Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis

被引：78

作者：

Gonzalez-Rey, Elena

Delgado, Mario ^{[1
]}

机构：

[1] CSIC, Inst Parasitol & Biomed, Granada 18100, Spain

[2] Univ Seville, Dept Bioquim Med & Biol Mol, E-41009 Seville, Spain

来源：

TRENDS IN MOLECULAR MEDICINE | 2007年 / 13卷 / 06期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1016/j.molmed.2007.04.003

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

The identification of regulatory T (Treg) cells as important regulators of self-tolerance has opened up new therapeutic avenues for the treatment of several human diseases associated with Treg dysfunction, including autoimmune diseases and transplantation. Recent evidence indicates that vasoactive intestinal peptide (VIP), an anti-inflammatory neuropeptide with therapeutic potential in various immune disorders, participates in maintaining immune tolerance by a novel mechanism of inducing the generation of Treg cells. We propose a Treg-cell-based immunotherapy approach for resetting the balance of immune homeostasis, which takes advantage of novel functions of VIP in immunoregulation.

引用

收藏

页码：241 / 251

页数：11

相关论文

共 66 条

[1]

Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease [J].

Abad, C ;

Martinez, C ;

Juarranz, MG ;

Arranz, A ;

Leceta, J ;

Delgado, M ;

Gomariz, RP .

GASTROENTEROLOGY, 2003, 124 (04) :961-971

[2]

Regulatory T-cell therapy: is it ready for the clinic? [J].

Bluestone, JA .

NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :343-349

[3]

Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3+CD4+CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAE [J].

Chen, Xin ;

Oppenheim, Joost J. ;

Winkler-Pickett, Robin T. ;

Ortaldo, John R. ;

Howard, O. M. Zack .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2006, 36 (08) :2139-2149

[4]

Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders [J].

Chorny, A ;

Gonzalez-Rey, E ;

Fernandez-Martin, A ;

Pozo, D ;

Ganea, D ;

Delgado, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (38) :13562-13567

[5]

Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response [J].

Chorny, A ;

Gonzalez-Rey, E ;

Fernandez-Martin, A ;

Ganea, D ;

Delgado, M .

BLOOD, 2006, 107 (09) :3787-3794

[6]

The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells [J].

Delgado, M ;

Gonzalez-Rey, E ;

Ganea, D .

JOURNAL OF IMMUNOLOGY, 2005, 175 (11) :7311-7324

[7]

Vasoactive intestinal peptide generates CD4+ CD25+ regulatory T cells in vivo [J].

Delgado, M ;

Chorny, A ;

Gonzalez-Rey, E ;

Ganea, D .

JOURNAL OF LEUKOCYTE BIOLOGY, 2005, 78 (06) :1327-1338

[8]

Delgado M, 1999, J IMMUNOL, V162, P1200

[9]

The significance of vasoactive intestinal peptide in immunomodulation [J].

Delgado, M ;

Pozo, D ;

Ganea, D .

PHARMACOLOGICAL REVIEWS, 2004, 56 (02) :249-290

[10]

Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease [J].

Delgado, M ;

Abad, C ;

Martinez, C ;

Laceta, J ;

Gomariz, RP .

NATURE MEDICINE, 2001, 7 (05) :563-568

← 1 2 3 4 5 6 7 →